10.11
0.59 (6.14%)
| Penutupan Terdahulu | 9.52 |
| Jumlah Dagangan | 80,276 |
| Harga / Buku (P/B) | 1.41 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -2.49 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.25% |
| Nisbah Semasa (MRQ) | 21.47 |
| Aliran Tunai Operasi (OCF TTM) | -39.28 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -26.34 M |
| Pulangan Atas Aset (ROA TTM) | -22.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Contineum Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Nilai 35% | 0.0 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | 0.0 |
| Masa 35% | -2.2 |
| AI Technical info | NA |
| Osilator Teknikal info | -2.0 |
| Purata Bergerak Teknikal info | -2.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -21.3% |
| Persetujuan Tonggak | ×1.00 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 1.5 |
| Skor Akhir | -0.93 |
|
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.82% |
| % Dimiliki oleh Institusi | 79.99% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |